Yale-New Haven neurosurgeons verifying effective eye tumor drug delivery localization with iMRI in VISIUS Surgical Theatre - On June 19, 2013, IMRIS announced that Yale-New Haven Hospital, New Haven, Connecticut, neurosurgeons are confirming effective chemotherapy delivery in treating eye cancer using intraoperative imaging within the VISIUS Surgical Theatre. Selective intra-arterial chemotherapy is a growing strategy for treating retinoblastomas - a rapid growth cancer in the eye primarily affecting infants. The technique allows for delivery of an increased concentration of the drug directly to the tumor and reduces the need to use systemically delivered chemotherapy, which can cause significant side effects. Using the VISIUS Surgical Theatre with iMRI during the treatment procedure is a novel approach to this strategy that permits Yale neurosurgeons to confirm successful delivery of chemotherapy at the tumor site.

IMRIS Announces U.S. Patent for Microsurgical Robot Concept - On May 22, 2013, IMRIS announced the allowance of a U.S. patent defining the foundational technologies for its SYMBIS™ Surgical System - a minimally invasive and MRI-compatible microsurgical robot system. Currently under development at IMRIS, the SYMBIS Surgical System is an image-guided, micro-neurosurgery robot that will combine surgeon-directed robotic arm manipulation with integrated high-definition 3D anatomical and MR imaging views to enable delicate brain micro-surgery. The system is being designed to work inside an intraoperative MRI within the VISIUS Surgical Theatre and provide a virtual extension of the surgeon's hands through robotic instruments with haptic feedback, motion refinement and intricate dexterity for use in the narrow surgical pathways of cranial neurosurgery.


IMRIS was issued three other new patents, including a U.S. system level patent for MR and X-ray imaging, and two product application patents for MR coils.

_________________________________
1 See "Non-GAAP Financial Measures" in the Company's Q2 2013 MD&A for further information on backlog.

Outlook

Miller stated, "Our year-to-date bookings are not where they need to be, due to a very sluggish environment for healthcare capital equipment. Addressing this is at the top of our priorities. We are implementing a new program that will make it easier for customers to purchase our systems. We are excited about our technologies and the enthusiastic response we are hearing from surgeons. However, based on headwinds in this market, our performance to date and expectations for the remainder of the year, we are lowering our 2013 sales outlook at this time. We continue to anticipate that quarter to quarter revenues and earnings will be lumpy, largely due to fluctuations in the number of installations each period."

More HCB News